Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 54Carcinoma, Non-Small-Cell Lung 22Neoplasms 17Neoplasm Metastasis 16Breast Neoplasms 16Triple Negative Breast Neoplasms 10Colorectal Neoplasms 9Stomach Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Ovarian Neoplasms 6Melanoma 5Carcinoma, Pancreatic Ductal 5Adenocarcinoma 5Small Cell Lung Carcinoma 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Hepatocellular 4Rectal Neoplasms 3Peritoneal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Hodgkin Disease 3Fallopian Tube Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Solid Tumor 2Sarcoma 2Prostatic Neoplasms 2Pancreatic Ductal Adenocarcinoma 2Nasopharyngeal Carcinoma 2

Interventions

Radiotherapy 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy × 130-nm albumin-bound paclitaxel × Clear all
NCT02207465 2025-11-19

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

Abramson Cancer Center at Penn Medicine

Phase 1 Active not recruiting
42 enrolled
Gastrointestinal

Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡